Peptonic Medical Files for Corporate Restructuring

The Board of Directors of Peptonic Medical AB (publ.) ("Peptonic" or "the Company") has today decided to submit an application for corporate restructuring. This decision is an extraordinary measure following a prolonged liquidity challenge and is intended to create the conditions for a stable and profitable business. External consultants have evaluated the situation and assessed that Peptonic has strong prospects of being granted the restructuring.

Peptonic has applied for corporate restructuring as an exceptional measure to address ongoing liquidity challenges. The Company acknowledges the potential impact on suppliers, customers, and partners but emphasizes that the measures being taken are unavoidable to secure its future and establish a stable and profitable business.

Despite economic challenges, Peptonic has successfully built a strong market position in the rapidly growing intimate self-care sector. Over recent years, the Company has successfully expanded its product portfolio, increased its international presence, and strengthened its position in clinically proven intimate self-care. The Company is optimistic about successful restructuring and remains focused on continuing developing its business, cost reduction, operational efficiency and achieving profitability.

"The decision to apply for corporate restructuring has not been taken lightly. However, it is a crucial step in addressing the Company's financial challenges and creating a solid foundation for the future. We are confident that this process will provide the best conditions for recovery, allowing us to strengthen our financial stability and ensure sustainable growth," says Anders Blom, Chairman of the Board.

The restructuring application is now subject to approval by the District Court. If granted, the process is expected to be completed within the next three to six months. During this period, Peptonic will implement financial and operational adjustments to build a resilient and profitable business for the future.

This disclosure contains information that PEPTONIC medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on March 11, 2025, 21.15 CET.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                                                                                             
Email: [email protected]                                                                                                                                         Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                         
PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.